Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693735 | 0.83 | ALDH1A1 (0.41) | SMN1; SMN2 | |
| SCHEMBL693502 | 0.77 | FDPS (0.41) | — | |
| SCHEMBL693058 | 0.77 | HSD11B1 (0.36) | KDM1ARCOR1 | |
| SCHEMBL693503 | 0.77 | FDPS (0.41) | — | |
| SCHEMBL693939 | 0.74 | MEN1 (0.42) | CNR2KMT2AS1PR1KDM1ARCOR1 | |
| SCHEMBL693696 | 0.73 | TSHR (0.42) | SMN1; SMN2NPC1S1PR1KDM1A | |
| SCHEMBL731252 | 0.71 | — | — | |
| SCHEMBL749951 | 0.71 | — | — | |
| SCHEMBL693033 | 0.71 | PGK1 (0.37) | — | |
| SCHEMBL693034 | 0.71 | PGK1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2422791-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8674088-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8586744-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2422791-A1 | Antiviral phosphinate compounds | Gilead Sciences, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7893264-B2 | viricides comprising phosphinic acid compounds and/or mixed with carriers, nucleoside analogues, interferons or pegylated interferons; treating hepatitis C or a hepatitis C associated disorders in animals; side effect reduction | GILEAD SCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| CN-101489564-A | Antiviral phosphinate compounds | GILEAD SCIENCES INC (US) | 2009-07-22 | — | — | CN | disclosed |
| EP-2043658-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008005565-A9 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | SMN1; SMN2 1818/4885CNR2 4794/4885NPC1 1297/4885 |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | SMN1; SMN2 1818/4885CNR2 4794/4885NPC1 1297/4885 |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | SMN1; SMN2 1818/4885CNR2 4794/4885NPC1 1297/4885 |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | HAVCR2, PHOSPHO1, EIF2AK2 | SMN1; SMN2 1610/4885CNR2 3817/4885NPC1 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.